Capricor Therapeutics, Inc. (CAPR)
8.37
+0.07
(+0.84%)
USD |
NASDAQ |
Sep 11, 16:00
8.40
+0.03
(+0.36%)
After-Hours: 20:00
Capricor Therapeutics Enterprise Value : 339.48M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 339.48M |
| September 10, 2026 | 335.42M |
| September 09, 2026 | 355.17M |
| September 08, 2026 | 379.58M |
| September 04, 2026 | 399.34M |
| September 03, 2026 | 392.36M |
| September 02, 2026 | 427.81M |
| September 01, 2026 | 434.78M |
| August 31, 2026 | 428.97M |
| August 28, 2026 | 410.38M |
| August 27, 2026 | 437.69M |
| August 26, 2026 | 397.01M |
| August 25, 2026 | 334.83M |
| August 24, 2026 | 248.25M |
| August 21, 2026 | 218.62M |
| August 20, 2026 | 250.29M |
| August 19, 2026 | 316.82M |
| August 18, 2026 | 264.52M |
| August 17, 2026 | 286.02M |
| August 14, 2026 | 239.54M |
| August 13, 2026 | 97.75M |
| August 12, 2026 | 96.59M |
| August 11, 2026 | 81.48M |
| August 10, 2026 | 76.83M |
| August 07, 2026 | 90.78M |
| Date | Value |
|---|---|
| August 06, 2026 | 96.01M |
| August 05, 2026 | 81.48M |
| August 04, 2026 | 95.43M |
| August 03, 2026 | 97.17M |
| July 31, 2026 | 76.83M |
| July 30, 2026 | 96.59M |
| July 29, 2026 | 234.89M |
| July 28, 2026 | 234.89M |
| July 27, 2026 | 259.58M |
| July 24, 2026 | 997.86M |
| July 23, 2026 | 1.005B |
| July 22, 2026 | 951.95M |
| July 21, 2026 | 1.003B |
| July 20, 2026 | 986.24M |
| July 17, 2026 | 982.75M |
| July 16, 2026 | 964.15M |
| July 15, 2026 | 1.036B |
| July 14, 2026 | 1.055B |
| July 13, 2026 | 1.051B |
| July 10, 2026 | 1.103B |
| July 09, 2026 | 1.161B |
| July 08, 2026 | 1.146B |
| July 07, 2026 | 1.144B |
| July 06, 2026 | 1.156B |
| July 02, 2026 | 1.202B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| REGENXBIO, Inc. | 606.74M |
| Cytokinetics, Inc. | 10.34B |
| Emergent BioSolutions, Inc. | 766.90M |
| Rigel Pharmaceuticals, Inc. | 825.83M |
| United Therapeutics Corp. | 18.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.73M |
| Total Expenses (Quarterly) | 40.73M |
| EPS Diluted (Quarterly) | -0.7032 |
| Earnings Yield | -29.26% |
| Normalized Earnings Yield | -29.26 |